Point72 Asset Management L.P. reduced its holdings in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 81.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 286,250 shares of the company's stock after selling 1,270,000 shares during the period. Point72 Asset Management L.P. owned about 1.39% of DBV Technologies worth $885,000 at the end of the most recent reporting period.
Separately, Boxer Capital Management LLC acquired a new stake in shares of DBV Technologies in the 4th quarter valued at $154,000. Institutional investors own 71.74% of the company's stock.
DBV Technologies Trading Up 0.6%
NASDAQ:DBVT traded up $0.06 during trading hours on Wednesday, hitting $9.35. 33,911 shares of the company traded hands, compared to its average volume of 189,870. DBV Technologies S.A. has a twelve month low of $2.20 and a twelve month high of $12.78. The firm has a 50-day moving average of $8.18 and a 200 day moving average of $5.38. The stock has a market capitalization of $256.10 million, a price-to-earnings ratio of -2.08 and a beta of -0.66.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Equities research analysts predict that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have weighed in on DBVT shares. JMP Securities raised their target price on DBV Technologies from $15.00 to $21.00 and gave the company a "market outperform" rating in a report on Tuesday. HC Wainwright boosted their price objective on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday, May 5th. Finally, Wall Street Zen raised shares of DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th.
Check Out Our Latest Analysis on DBV Technologies
About DBV Technologies
(
Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
